Pharmacokinetics (PK) and pharmacodynamics (PD) of orally (PO) administered midazolam (MDZ) in the presence and absence of intravenous (IV) flumazenil (F) in healthy volunteers.

被引：3
|
作者：
Lawendy, NM
Holt, JL
Fullerton, T
Nafziger, AN
Snyder, PJ
Victory, J
Bertino, JS
机构：
[1] Bassett Healthcare, Groton, CT USA
[2] Pfizer Global Res & Dev, Groton, CT USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2003年 / 73卷 / 02期
关键词：
D O I：
10.1016/S0009-9236(03)90411-5
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P15 / P15
页数：1
相关论文
共 14 条
  • [1] The effect of rifaximin on the pharmacokinetics (PK) of single doses of intravenous (IV) and oral (PO) midazolam in healthy volunteers.
    King, A
    Laurie, R
    Connolly, M
    Kamm, A
    Boxenbaum, W
    Kastrissios, H
    Trapnell, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P66 - P66
  • [2] Pharmacokinetics (PK) and pharmacodynamics (PD) of interferon β-1a in healthy volunteers.
    Buchwalder, PA
    Buclin, T
    Trinchard, I
    Munafo, A
    Biollaz, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 166 - 166
  • [3] Pharmacokinetics and pharmacodynamics of low doses of midazolam administered intravenously and orally to healthy volunteers
    Misaka, Shingen
    Uchida, Shinya
    Imai, Hiromitsu
    Inui, Naoki
    Nishio, Shinichiro
    Ohashi, Kyoichi
    Watanabe, Hiroshi
    Yamada, Shizuo
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2010, 37 (03): : 290 - 295
  • [4] Pharmacokinetics (PK) and pharmacodynamics (PD) of a combination of tramadol (T) and acetaminophen (A) in healthy volunteers.
    Rollason, V
    Vogt, N
    Deloche, C
    Piguet, V
    Dayer, R
    Desmeules, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P52 - P52
  • [5] The pharmacokinetics (PK) and pharmacodynamics (PD) of VX-702, a novel, oral p38MAP kinase inhibitor, in healthy volunteers.
    Godfrey, C
    Mohanlal, R
    Merica, E
    Ette, E
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (02) : P52 - P52
  • [6] EVALUATION OF THE TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ORALLY ADMINISTERED DWP05195, A NEW TRPV1 ANTAGONIST IN HEALTHY ADULT MALE VOLUNTEERS.
    Lee, S.
    Jiang, F.
    Lee, J.
    Chung, J.
    Jang, I.
    Lee, H.
    Yu, K.
    Jang, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S77 - S77
  • [7] SAFETY, TOLERABILITY, PHARMACOKINETICS (PK), AND PHARMACODYNAMICS (PD) OF AZD7594 AFTER SINGLE AND MULTIPLE ASCENDING INHALED DOSES IN HEALTHY MALE VOLUNTEERS.
    Chen, Y.
    Prothon, S.
    Aurivillius, M.
    Eriksson, U. G.
    Aggarwal, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S39 - S39
  • [8] Oblimersen can be administered by subcutaneous (SC) and brief intravenous (IV) infusion: Clinical pharmacokinetics and pharmacodynamics (PK/PD) in patients with advanced cancer
    Lin, C.
    Papadopoulos, K.
    Patnaik, A.
    Sankhala, K.
    Takimoto, C. H.
    Rodon, J.
    Julian, T.
    Brown, B. D.
    Tolcher, A. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] OM11-62MF: Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Novel Anti-CD40 Antibody in Healthy Volunteers.
    Slade, A.
    Koo, P.
    Espie, P.
    Tomek, C.
    Rush, J.
    Klupp, J.
    Lee, D.
    TRANSPLANTATION, 2014, 98 : 115 - 115
  • [10] OM11-62MF: Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Novel Anti-CD40 Antibody in Healthy Volunteers.
    Slade, A.
    Koo, P.
    Espie, P.
    Tomek, C.
    Rush, J.
    Klupp, J.
    Lee, D.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 115 - 115
12